



Making Science work for you...

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Unaudited Financial Results for the Quarter and Half year ended 30th September, 2009

[Rs. in Lacs]

[Rs. in Lacs]

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2009	2008	2009	2008	2009		2009	2008	2009	2008	2009
93311	94050	182947	176710	351798	Net sales/Income from operations	62736	67900	123330	129525	243072
353	625	850	1067	2434	Other Operating Income	237	563	628	788	1138
93664	94675	183797	177777	354232	Total income	62973	68463	123958	130313	244210
77879	80431	154374	149873	310893	Total expenditure	48804	54283	95783	102986	208352
342	(5128)	1226	(5500)	(7813)	a) (Increase)/Decrease in stock in trade and work in progress	537	(4153)	1607	(4073)	(2811)
4511	3448	8679	6188	11349	b) Purchase of traded goods	4444	2639	8021	4677	10668
32023	37168	62952	68025	131488	c) Raw & process materials consumed	26160	32841	51454	60478	113470
5333	6221	10739	11264	21116	d) Stores, spares, chemicals, catalyst & packing material consumed	2672	3665	5312	6703	11666
5780	6313	10528	11549	19791	e) Power & fuel	5305	5705	9597	10723	18079
1796	2475	3301	4093	8675	f) Other manufacturing expenses	1389	1845	2466	3257	6364
18846	17164	37168	29720	65749	g) Staff cost	4321	3885	8522	7440	15600
3079	4107	6159	7472	16324	h) Depreciation	1629	1761	3185	3433	7462
(2066)	1063	(2500)	551	10429	i) Exchange Loss/(Gain)	(2016)	1744	(3055)	1500	10188
8235	7600	16122	16511	33785	j) Selling, general & admin. expenses	4363	4351	8674	8848	17666
15785	14244	29423	27904	43339	Operating profit before Other Income & Interest	14169	14180	28175	27327	35858
302	83	516	381	1816	Other Income	284	65	468	128	674
16087	14327	29939	28285	45155	Profit before Interest & Exceptional Items	14453	14245	28643	27455	36532
3632	2205	7701	3582	10704	Interest (Net)	2557	803	5479	1319	5435
12455	12122	22238	24703	34451	Profit after Interest but before Exceptional Items	11896	13442	23164	26136	31097
4277	17419	(627)	28178	4793	Exceptional items	3740	14425	(1635)	25184	3794
8178	(5297)	22865	(3475)	29658	Profit from Ordinary Activities before tax	8156	(983)	24799	952	27303
2396	1660	4630	2273	2672	Tax Expenses (Net)	2607	1456	4747	1940	1229
5782	(6957)	18235	(5748)	26986	Net profit from Ordinary Activities after tax	5549	(2439)	20052	(988)	26074
-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-
14	(685)	(115)	(752)	(1332)	Minority Interest	-	-	-	-	-
5768	(6272)	18350	(4996)	28318	Net profit after Minority Interest	5549	(2439)	20052	(988)	26074
1475	1475	1475	1475	1475	Paid-up share capital (Face value per share Re. 1)	1475	1475	1475	1475	1475
				125279	Reserves (excluding revaluation reserve)					132463
3.91	(4.25)	12.44	(3.40)	19.22	Basic (Rs.)	3.76	(1.65)	13.59	(0.67)	17.70
3.38	(3.51)	10.74	(2.79)	16.56	Diluted (Rs.)	3.24	(1.36)	11.73	(0.55)	15.25
72565234	73151374	72565234	73151374	73121834	Public shareholding	72565234	73151374	72565234	73151374	73121834
49.18	49.58	49.18	49.58	49.56	- Number of shares (Re. 1 each)	49.18	49.58	49.18	49.58	49.56
					- Percentage of shareholding					
16605000		16605000		16421000	Promoters and promoter group Shareholding	16605000		16605000		16421000
22.15		22.15		22.07	a) Pledged/Encumbered	22.15		22.15		22.07
					- Number of shares					
					- Percentage of shares					
					(as a % of the total shareholding of promoter and promoter group)					
11.25		11.25		11.13	- Percentage of shares	11.25		11.25		11.13
					(as a % of the total share capital of the company)					
58372024		58372024		57999424	b) Non-Encumbered	58372024		58372024		57999424
77.85		77.85		77.93	- Number of shares	77.85		77.85		77.93
					- Percentage of shares					
					(as a % of the total shareholding of promoter and promoter group)					
39.56		39.56		39.31	- Percentage of shares	39.56		39.56		39.31
					(as a % of the total share capital of the company)					

Segment wise Revenue, Results & Capital Employed (under Clause 41 of the Listing Agreement)										
CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2009	2008	2009	2008	2009		2009	2008	2009	2008	2009
65315	58586	127033	110851	232370	Segment revenue					
28235	35567	56251	66034	119751	a. Pharmaceuticals and Life Sciences Products & Services	34726	32392	67480	63624	123619
93550	94153	183284	176885	352121	b. Industrial & Performance Products	28249	35611	56187	66076	119776
239	103	337	175	323	Total	62975	68003	123667	129700	243395
93311	94050	182947	176710	351798	Less : Inter segment revenue	239	103	337	175	323
65139	58586	126857	110851	232370	Net sales/Income from operations	62736	67900	123330	129525	243072
28172	35464	56090	65859	119428	a. Pharmaceuticals and Life Sciences Products & Services	34550	32392	67304	63624	123619
93311	94050	182947	176710	351798	b. Industrial & Performance Products	28186	35508	56026	65901	119453
					Total	62736	67900	123330	129525	243072
15052	9005	27555	20175	42224	Segment results (profit+/-)/loss(-) before tax and interest from each segment					
2131	5666	5925	9821	10930	a. Pharmaceuticals and Life Sciences Products & Services	13407	9145	26259	19514	33698
17183	14671	33480	29996	53154	b. Industrial & Performance Products	2143	5672	5925	9829	11035
3632	2205	7701	3582	10704	Total	15550	14817	32184	29343	44733
3394	17834	8594	30255	19636	Less : i. Interest	2557	803	5479	1319	5435
1979	(71)	(5680)	(366)	(6844)	ii. Other un-allocable expenditure (including exceptional items)	3024	15060	7317	27200	18577
8178	(5297)	22865	(3475)	29658	iii. Un-allocable Income (including exceptional items)	1813	(63)	(5411)	(128)	(6582)
					Total profit before tax	8156	(983)	24799	952	27303
425707	396046	425707	396046	409275	Capital Employed (Segment assets less Segment liabilities)					
64751	75852	64751	75852	75248	a. Pharmaceuticals and Life Sciences Products & Services	138968	130847	138968	130847	127119
490458	471898	490458	471898	484523	b. Industrial & Performance Products	64452	75727	64452	75727	75002
44779	4558	44779	4558	44744	Total Capital employed in segments	203420	206574	203420	206574	202121
535237	476456	535237	476456	529267	Add: Un-allocable corporate assets less liabilities	205211	145451	205211	145451	197037
					Total capital employed in the Company	408631	352025	408631	352025	399158

Notes:

- Exceptional items include :
 - Amortisation of Foreign Currency Monetary Item Translation Difference Account Rs. 1325 Lacs (Consolidated Rs. 1497 Lacs) for Q2-FY 2010 and Rs.2628 Lacs (Consolidated Rs. 3707 Lacs) for H1-FY 2010.
 - Loss of Rs 2415 Lacs (Consolidated Rs. 2780 Lacs) for Q2-FY 2010 and gain of Rs. 4263 Lacs (Consolidated Rs.4334 Lacs) for H1-FY 2010 on Mark to Market unassigned forward contracts/interest rate swaps outstanding as on 30th September, 2009.
- The company had opted for accounting of exchange difference arising on reporting of long term monetary items under AS 11 in line with the Companies (Accounting Standard) Amendment Rules 2009 in quarter ending March 2009 for the entire financial year 2008-09. Accordingly the said exchange loss in previous year of Rs 14010 Lacs (Consolidated Rs.17004 Lacs) for Q2-FY 2009 and Rs. 24742 Lacs (Consolidated Rs. 27736 Lacs) for H2-FY 2009 has been recast to fixed assets / foreign currency monetary items translation difference account (FCMITDA) at the year end. The balance in FCMITDA of Rs.7648 Lacs (Consolidated Rs.10990 Lacs) subject to further fluctuations on reporting date, shall be amortised till March 2011.
- In order to bring uniformity in accounting policy, beginning 1st April 2009 , the depreciation method, in respect of certain assets has been changed from written down value method to straight line method with retrospective effect as per AS 6 and consequent effect is cumulative lower depreciation charge by Rs 3117 Lacs (Consolidated Rs 6603 Lacs) . A pro-rata amount of Rs 779 Lacs (Consolidated Rs 1651 Lacs) has been reduced in depreciation for the current quarter Q2-FY 2010 and Rs 1558 Lacs (Consolidated Rs. 3302 Lacs) has also been reduced from the depreciation for six months ended 30th September 2009 . Due to effect of such change in policy, the depreciation charge in the current year is also lower by Rs 89 Lacs (Consolidated Rs. 153 Lacs) for the Q2-FY 2010 and Rs 178 Lacs (consolidated - Rs 293 Lacs) for H1-FY 2010.
- During the quarter, the Company through its wholly owned subsidiary has invested USD \$ 1 million in the equity share capital of Vanthys Pharmaceuticals Pvt Ltd., a 50:50 Joint Venture with Eli Lilly.
- Information on investors complaints for the quarter (Nos.): Opening Balance – Nil, New 17, Disposals 17, Closing Balance – Nil.
- The above un-audited results were subjected to limited review by the auditors of the company and were approved by the Board of Directors at its meeting held on 22nd October, 2009.

For Jubilant Organosys Ltd.

Place : Noida
Dated : 22nd October, 2009

Shyam S Bhartia
Chairman & Managing Director

visit us at www.jubl.com